scholarly journals Clinical effectiveness of combination therapy with dulaglutide, SGLT2 inhibitor and metformin with or without insulin in Indian adults with type 2 diabetes: a real-world retrospective study

2020 ◽  
Vol 9 (4) ◽  
pp. 233-238
Author(s):  
Supratik Bhattacharyya
Keyword(s):  
Type 2 Diabetes ◽  
Retrospective Study ◽  
Combination Therapy ◽  
Real World ◽  
Sglt2 Inhibitor ◽  
Clinical Effectiveness

scholarly journals Real-World Effectiveness of Liraglutide Versus Dulaglutide In Japanese Patients With Type 2 Diabetes: A Retrospective Study

2021 ◽  
Author(s):  
Kenichi Tanaka ◽  
Yosuke Okada ◽  
Akemi Tokutsu ◽  
Yoshiya Tanaka
Keyword(s):  
Type 2 Diabetes ◽  
Retrospective Study ◽  
Real World ◽  
Clinical Effectiveness ◽  
Patient Characteristics ◽  
Japanese Patients ◽  
Hierarchical Regression ◽  
Contributing Factors ◽  
Real World Data

Abstract Real-world data comparing the effectiveness of various glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in type 2 diabetes mellitus (T2DM) are limited. We investigated the clinical effectiveness of liraglutide and dulaglutide in Japanese T2DM in a real-world setting. This retrospective study included 179 patients with T2DM who were treated with GLP-1 RA for at least 12 months (liraglutide, n=97; dulaglutide, n=82). Changes in glycated hemoglobin (HbA1c) at the end of 12-month treatment were evaluated. Compared with the liraglutide group, the dulaglutide group included significantly older patients with longer disease duration, lower body mass index, and higher proportion of dementia cases. HbA1c was significantly lower at 12 months in both groups (liraglutide, 8.9 to 7.6%; dulaglutide, 8.8 to 7.5%). Hierarchical regression analysis showed no differences in the extent of changes in HbA1c at 12 months between the two agents, after adjustment for differences in patient characteristics and drug adjustments during the 12-month period. High baseline HbA1c, the addition of GLP-1 RA treatment, and in-hospital initiation of GLP-1 RA treatment were identified as significant contributing factors to HbA1c reduction. Although patient characteristics were different between the two treatment groups, comparable HbA1c-lowering effects were noted in real-world settings.

Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real-world retrospective study conducted in Spain

2018 ◽  
Vol 35 (11) ◽  
pp. 1605-1612 ◽  
Author(s):  
F. Gomez-Peralta ◽  
A. Lecube ◽  
A. Fernández-Mariño ◽  
I. Alonso Troncoso ◽  
C. Morales ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Retrospective Study ◽  
Real World ◽  
Clinical Effectiveness ◽  
Interindividual Differences

scholarly journals Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis

2019 ◽  
Vol 8 (1) ◽  
pp. 45 ◽  
Author(s):  
Tamara Y. Milder ◽  
Sophie L. Stocker ◽  
Christina Abdel Shaheed ◽  
Lucy McGrath-Cadell ◽  
Dorit Samocha-Bonet ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Combination Therapy ◽  
Low Dose ◽  
Meta Analysis ◽  
Sglt2 Inhibitor ◽  
Cochrane Library ◽  
High Dose ◽  
Dose Combination ◽  
Inhibitor Combination

Background: Guidelines differ with regard to indications for initial combination pharmacotherapy for type 2 diabetes. Aims: To compare the efficacy and safety of (i) sodium-glucose cotransporter 2 (SGLT2) inhibitor combination therapy in treatment-naïve type 2 diabetes adults; (ii) initial high and low dose SGLT2 inhibitor combination therapy. Methods: PubMed, Embase and Cochrane Library were searched for randomised controlled trials (RCTs) of initial SGLT2 combination therapy. Mean difference (MD) for changes from baseline (HbA1c, weight, blood pressure) after 24–26 weeks of treatment and relative risks (RR, safety) were calculated using a random-effects model. Risk of bias and quality of evidence was assessed. Results: In 4 RCTs (n = 3749) there was moderate quality evidence that SGLT2 inhibitor/metformin combination therapy resulted in a greater reduction in HbA1c (MD (95% CI); −0.55% (−0.67, −0.43)) and weight (−2.00 kg (−2.34, −1.66)) compared with metformin monotherapy, and a greater reduction in HbA1c (−0.59% (−0.72, −0.46)) and weight (−0.57 kg (−0.89, −0.25)) compared with SGLT2 inhibitor monotherapy. The high dose SGLT2 inhibitor/metformin combination resulted in a similar HbA1c but greater weight reduction; −0.47 kg (−0.88, −0.06) than the low dose combination therapy. The RR of genital infection with combination therapy was 2.22 (95% CI 1.33, 3.72) and 0.69 (95% CI 0.50, 0.96) compared with metformin and SGLT2 inhibitor monotherapy, respectively. The RR of diarrhoea was 2.23 (95% CI 1.46, 3.40) with combination therapy compared with SGLT2 inhibitor monotherapy. Conclusions: Initial SGLT2 inhibitor/metformin combination therapy has glycaemic and weight benefits compared with either agent alone and appears relatively safe. High dose SGLT2 inhibitor/metformin combination therapy appears to have modest weight, but no glycaemic benefits compared with the low dose combination therapy.

Sign in / Sign up

Export Citation Format

Share Document